Search

Background: Computed tomography (CT) and bone scintigraphy (BS) are the imaging modalities currently used for distant metastasis staging of prostate cancer (PCa). Objective: To compare standard staging modalities with newer and potentially more accurate imaging modalities. Design, setting, and participants: This prospective, single-centre trial (NCT03537391) enrolled 80 patients with newly diagnosed high-risk PCa (International Society of Urological Pathology grade group >= 3 and/or prostate-specific antigen [PSA] >= 20 and/or cT >= T3; March 2018-June 2019) to undergo primary metastasis staging with two standard and three advanced imaging modalities. Outcome measurements and statistical analysis: The participants underwent the following five imaging examinations within 2 wk of enrolment and without a prespecified sequence: BS, CT, Tc-99m-hydroxymethylene diphosphonate (Tc-99m-HMDP) single-photon emission computed tomography (SPECT)-CT, 1.5 T whole-body magnetic resonance imaging (WBMRI) using diffusion-weighted imaging, and F-18-prostate-specific membrane antigen-1007 (F-18-PSMA-1007) positron emission tomography(PET)-CT. Each modality was reviewed by two independent experts blinded to the results of the prior studies, who classified lesions as benign, equivocal, or malignant. Pessimistic and optimistic analyses were performed to resolve each equivocal diagnosis. The reference standard diagnosis was defined using all available information accrued during at least 12 mo of clinical follow-up. Patients with equivocal reference standard diagnoses underwent MRI and/or CT to search for the development of anatomical correspondence. PSMA PET-avid lesions without histopathological verification were rated to be malignant only if there was a corresponding anatomical finding suspicious for malignancy at the primary or follow-up imaging. Results and limitations: Seventy-nine men underwent all imaging modalities except for one case of interrupted MRI. The median interval per patient between the first and the last imaging study was 8 d (interquartile range [IQR]: 6-9). The mean age was 70 yr (standard deviation: 7) and median PSA 12 ng/mL (IQR:7-23). The median follow-up was 435 d (IQR: 378-557). Metastatic disease was detected in 20 (25%) patients. The imaging modality F-18-PSMA-1007 PET-CT had superior sensitivity and highest inter-reader agreement. The area under the receiver-operating characteristic curve (AUC) values for bone metastasis detection with PSMA PET-CT were 0.90 (95% confidence interval [CI]: 0.85-0.95) and 0.91 (95% CI: 0.87-0.96) for readers 1 and 2, respectively, while the AUC values for BS, CT, SPECT-CT, and WBMRI were 0.71 (95% CI: 0.58-0.84) and 0.8 (95% CI: 0.67-0.92), 0.53 (95% CI: 0.39-0.67) and 0.66 (95% CI: 0.54-0.77), 0.77 (95% CI: 0.65-0.89) and 0.75 (95% CI: 0.62-0.88), and 0.85 (95% CI: 0.74-0.96) and 0.67 (95% CI: 0.54-0.80), respectively, for the other four pairs of readers. The imaging method F-18-PSMA-1007 PET-CT detected metastatic disease in 11/20 patients in whom standard imaging was negative and influenced clinical decision making in 14/79 (18%) patients. In 12/79 cases, false positive bone disease was reported only by PSMA PET-CT. Limitations included a nonrandomised study setting and few histopathologically validated suspicious lesions. Conclusions: Despite the risk of false positive bone lesions, F-18-PSMA-1007 PET-CT outperformed all other imaging methods studied for the detection of primary distant metastasis in high-risk PCa. Patient summary: In this report, we compared the diagnostic performance of conventional and advanced imaging. It was found that F-18-prostate-specific membrane antigen-1007 positron emission tomography/computed tomography (F-18-PSMA-1007 PET-CT) was superior to the other imaging modalities studied for the detection of distant metastasis at the time of initial diagnosis of high-risk prostate cancer. PSMA PET-CT also appears to detect some nonmetastatic bone lesions. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.

Computed tomography (CT) and bone scintigraphy (BS) are the imaging modalities currently used for distant metastasis staging of prostate cancer (PCa).To compare standard staging modalities with newer and potentially more accurate imaging modalities.This prospective, single-centre trial (NCT03537391) enrolled 80 patients with newly diagnosed high-risk PCa (International Society of Urological Pathology grade group ≥3 and/or prostate-specific antigen [PSA] ≥20 and/or cT ≥ T3; March 2018-June 2019) to undergo primary metastasis staging with two standard and three advanced imaging modalities.The participants underwent the following five imaging examinations within 2 wk of enrolment and without a prespecified sequence: BS, CT,Seventy-nine men underwent all imaging modalities except for one case of interrupted MRI. The median interval per patient between the first and the last imaging study was 8 d (interquartile range [IQR]: 6-9). The mean age was 70 yr (standard deviation: 7) and median PSA 12 ng/mL (IQR:7-23). The median follow-up was 435 d (IQR: 378-557). Metastatic disease was detected in 20 (25%) patients. The imaging modalityDespite the risk of false positive bone lesions,In this report, we compared the diagnostic performance of conventional and advanced imaging. It was found that

Background: Computed tomography (CT) and bone scintigraphy are the imaging modalities currently used for primary metastasis staging of high-risk prostate cancer (PCa). This trial compared these standard staging modalities with potentially more accurate imaging modalities: single photon emission computed tomography-CT (SPECT-CT), magnetic resonance imaging (MRI), prostate specific membrane antigen positron emission tomography (PSMA PET). Methods: This prospective, registered, single-centre, open-label, single-arm trial enrolled patients with primary high-risk PCa. Results of bone scintigraphy and CT were compared with 99mTc-HMDP SPECT-CT, 1.5T whole-body MRI using diffusion-weighted imaging and 18 F-PSMA-1007 PET-CT. Each imaging modality was reviewed by two independent experts blinded for the other modalities. The lesions were classified as benign, equivocal or malignant. Pessimistic and optimistic analyses were performed to resolve equivocal lesion status. Based on clinical data, including follow-up investigations, the best valuable comparator was defined at lesion level in multidisciplinary consensus meetings. Findings: 79 men were included and underwent all imaging modalities, except for one cancelled MRI due to claustrophobia. Mean age was 70 years and median PSA 12 ng/ml (range: 3-2000). Metastatic disease was detected in 27 (34%) patients. In pessimistic and optimistic analysis at patient, region and lesion levels, PSMA PET-CT was superior to all other modalities concerning sensitivity, and the area under curve values (AUC) at the bone region, while maintaining high specificity and demonstrating the highest inter-reader agreement. AUC for detection of bone metastasis for PSMA PET-CT was 0·94 (95%Cl;0·90-0·99) and 0·96 (95%CI;0·92-0·99) (reader 1, and reader 2, respectively) while AUC for all other modalities was in the range of 0·55-0·76. PSMA PET-CT revealed metastatic disease in 18/27 patients where standard imaging was negative. Interpretation: 18F-PSMA-1007 PET-CT outperformed other imaging methods in primary metastasis staging of high-risk PCa. We recommend further evaluation of this method as a new reference standard. Trial Registration number: (ClinicalTrials.gov NCT03537391). Funding Statement: This study was financially supported by grants from Finnish Government Research and Development Funds for Medical Research, Turku University Hospital and TYKS-SAPA Research Fund. Declaration of Interests: Dr. Anttinen reports grants from Profound Medical Inc, Finnish Urological Research Foundation and Finnish Urological Association, outside the submitted work. Dr. Ettala reports non-financial support from Ferring Pharmaceuticals Inc, SwanMedica and Pierre-Fabre Pharma Norden AB, and personal fees from Astellas, outside the submitted work. Dr. Sandell reports personal fees from Roche, outside the submitted work. Dr. Taimen reports personal fees from Roche, AstraZeneca and MSD, and non-financial support from MSD, all outside the submitted work. Dr. Bostrom reports grants from the Cancer Foundation Finland, personal fees from Profound Medical Inc and Janssen-Cilag Company, outside the submitted work. The other authors declare that there is no conflict of interest regarding the publication of this article. Ethical Approval Statement: The trial protocol, included in the Supplemental material, was approved by the ethics committee of the Hospital District of Southwest Finland, and written informed consent was obtained from all participants. The trial was performed in accordance with the principles of the Declaration of Helsinki.

PURPOSE The diversity of the dynamic radionuclide renal imaging (renography) study protocols sets challenges for the overall study quality, therefore raising a need for national quality control. The aim of this study was to encourage the standardization of renography in Finland and to evaluate the development after a previous study performed in 1997. METHODS The new Heikkinen phantom was imaged in each of the 20 participating nuclear medicine laboratories. The results were interpreted in the manner of a regular patient study, and reconstructions and printouts were made according to the clinical routines of each laboratory. Four quantitative parameters were calculated and compared between laboratories. The reports were also assessed in a blind test. RESULTS The average error in T(max) values ranged from -5 to 7% (-29 to +18% in 1997), in T(1/2) from 0 to 35% (-43 to +66%), in RCA20 from -20 to +28% (-50 to +82%) and in relative uptake from -3 to 5%. The difference from average in relative uptake ranged from -4 to 5% (-21 to +36%). CONCLUSION The results showed that the errors in T(max) and relative uptake were generally within quite acceptable margins, and the variation in quantitative parameters between laboratories was shown to be smaller than 14 years earlier. The reason might be the use of new software packages as well as increased efforts to improve the quality of the studies.

The aim of the study was to evaluate quality of myocardial perfusion single-photon emission tomography (SPET) imaging in Finnish hospitals. Nineteen nuclear medicine departments participated in the study. A myocardial phantom simulating clinical stress and rest conditions was filled with routinely used isotope solution (technetium-99m or thallium-201). The cardiac insert included three reversible defects (simulating ischaemia): 30x30x14 mm(3) septal (90% recovery at rest), 30x20x14 mm(3) posterobasal (full recovery) and 20x20x14 mm(3) lateral (full recovery). There were two fixed defects (simulating infarct): 30x20x14 mm(3) postero-apical and 10x10x6 mm(3) apical. The phantom was imaged and interpreted as a myocardial perfusion patient. Reconstruction, printout and reporting were performed according to the clinical routine of each centre. Three nuclear medicine specialists anonymously evaluated the quality of the image sets. The visual scores of the experts were ranked from 1 to 5. Additionally, points from 0 to 8 were given to research reports according to how well perfusion defects were detected. Quantitative points were calculated by comparing background-subtracted and -normalized counts from 12 regions of interest between stress and rest images. Results for technetium studies (12 departments) were better than those for thallium (7 departments). The average visual scores of the experts were 3.7+/-0. 9 for all image sets, 3.2+/-0.5 for thallium users and 3.9+/-0.6 for technetium users (P=0.003). Five laboratories received a low score which, according to the specialists, is barely sufficient for limited clinical use. Average points for the reports were 5.6+/-2.1, 4.9+/-1.5 and 6.5+/-1.7 (P=0.051), and for the quantitation 8.2+/-1. 0, 7.9+/-0.4 and 8.4+/-1.1 (P=0.185), respectively. Seven out of 22 interpreters did not detect the lateral 20x20x14 mm(3) defect; five of them used thallium. This study demonstrated the heterogeneity of myocardial perfusion SPET in Finland. The participating laboratories used a wide scale of methods and, sometimes, inappropriate imaging protocols. The need for quality assurance in nuclear cardiology, correct use of SPET instrumentation and objective comparison of clinical studies is evident. The method described is suitable for external quality assurance and quality improvement of myocardial SPET imaging, and is recommended for regular use in nuclear medicine.

Epidemiological studies have suggested that patients with rheumatoid arthritis (RA) have increased mortality due to cardiovascular disease. We studied cardiac performance in 12 asymptomatic male patients with RA and 14 control subjects to elucidate early disturbances in cardiac function. In echocardiography, isovolumic relaxation time was longer (64 +/- 6 vs. 49 +/- 3 ms, mean +/- SEM, P = 0.010) and peak filling rate (134 +/- 10 vs. 159 +/- 6 mm s-1, P = 0.015) lower in patients with RA than in control subjects, reflecting an impairment in left ventricular diastolic function. Left ventricular systolic function assessed by radionuclide angiocardiography at rest and during exercise was similar in both groups. There were no differences between the patients with RA and control subjects in the heart rate, systolic blood pressure and oxygen uptake during peak exercise. Left ventricular diastolic function is impaired in spite of normal left ventricular systolic function in patients with RA without clinically evident cardiovascular disease and this may contribute to the excess of cardiovascular mortality in patients with RA.

The aim of this study was to evaluate the quality of dynamic radionuclide renal imaging in Finland. Nineteen nuclear medicine departments participated. A functional renal phantom was imaged and interpreted as a patient-like study. Reconstruction and printouts were performed according to the clinical routine of each laboratory. Three nuclear medicine specialists anonymously evaluated the quality of the image sets. The visual scores of the experts were ranked from one to five. In addition, several numerical time-activity parameters were calculated and compared between the laboratories. The average visual scores of the experts for the image sets were 3.2+/-0.5 (range 2.4-4.2). Only two laboratories received a score value of 4 or higher. The average error for the time to reach maximum activity (T(max)) ranged from -29 to +18% and for the washout time to reach half activity from maximum activity (T(1/2)) ranged from -43 to +66%. These results suggest that the difference in calculated parameters between laboratories is most probably due to variations in study protocols and analysis programmes. The need for external quality assurance and quality improvement in nuclear renal imaging is evident and is recommended for regular use.

The aim of the study was to evaluate the quality of routine brain perfusion single-photon emission tomography (SPET) images in Finnish nuclear medicine laboratories. Twelve laboratories participated in the study. A three-dimensional high resolution brain phantom (Data Spectrum's 3D Hoffman Brain Phantom) was filled with a well-mixed solution of technetium-99m (110 MBq), water and detergent. Acquisition, reconstruction and printing were performed according to the clinical routine in each centre. Three nuclear medicine specialists blindly evaluated all image sets. The results were ranked from 1 to 5 (poor quality-high quality). Also a SPET performance phantom (Nuclear Associates' PET/SPECT Performance Phantom PS 101) was filled with the same radioactivity concentration as the brain phantom. The parameters for the acquisition, the reconstruction and the printing were exactly the same as with the brain phantom. The number of detected "hot" (from 0 to 8) and "cold" lesions (from 0 to 7) was visually evaluated from hard copies. Resolution and contrast were quantified from digital images. Average score for brain phantom images was 2.7 +/- 0.8 (range 1.5-4.5). The average diameter of the "hot" cylinders detected was 16 mm (range 9.2-20.0 mm) and that of the "cold" cylinders detected, 11 mm (5.9-14.3 mm) according to visual evaluation. Quantification of digital images showed that the hard copy was one reason for low-quality images. The quality of the hard copies was good only in four laboratories and was amazingly low in the others when comparing it with the actual structure of the brain phantom. The described quantification method is suitable for optimizing resolution and contrast detectability of hard copies. This study revealed the urgent need for external quality assurance of clinical brain perfusion SPET images.

10 subjects with Hb Linkoping (beta 36 Pro greater than Thr), a high-affinity hemoglobin variant, with a P50 of 2.2 kPa (16.5 mm Hg) were investigated before and 3-4 days after normovolemic hemodilution. Blood hemoglobin concentration decreased from 176 +/- 13 (SD) to 146 +/- 15 g l-1 and the red cell volume from 2.77 +/- 0.83 to 2.23 +/- 0.67 l. Maximal oxygen consumption decreased slightly by 2.7 +/- 3.8 ml min-1 kg-1 and maximal exercise power by 11 +/- 23 W; these changes were, however, not statistically significant. Maximal heart rate was unchanged (-1.1 +/- 6.4 beats min-1) while submaximal heart rate was consistently increased on comparable loads after hemodilution compared to before. The exercise ECG was normal both before and after hemodilution. Capillary lactate levels at exercise were always higher after hemodilution than before. Cerebral blood flow was normal both before and after hemodilution in all subjects but one who had a high flow. The grey matter blood flow increased slightly but significantly by 8.6 +/- 10.3 ml min-1 100 g-1 from before to after hemodilution. The results indicate that subjects with Hb Linkoping have only limited benefit from their increased blood hemoglobin concentration.

Myocardial free fatty acid metabolism and left ventricular function were evaluated in 15 middle-aged patients with non-insulin-dependent diabetes mellitus (NIDDM) and in 8 healthy control subjects. The study subjects had no evidence of coronary heart disease on the basis of clinical history, exercise ECG or myocardial perfusion scintigraphy. During peak exercise, iodine-123 hepatadecanoic acid (HDA) was intravenously injected. Myocardial activity distribution of 123I-HDA was measured 10, 30, and 50 min after exercise using single-photon emission tomography (SPET); and then further corrected by free 123I-iodine. Venous blood samples were drawn for detecting the plasma activity of 123I. The net extraction of 123I-HDA into the myocardium was obtained by dividing the corrected tissue 123I concentration by the integral of the plasma time activity curve. The net extraction was 0.40 ± 0.06 min−1 (mean ± SD) patients with NIDDM and 0.38 ± 0.06 min−1 in control subjects (P>0.1), respectively. The faster elimination rate of 123I-HDA was found in patients with NIDDM (0.029±0.008 min−1) than in control subjects (0.022±0.004 min−1; P